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ABSTRACT 
 
The BRMS1, BReast cancer Metastasis Supressor 1 gene suppresses cancer metastasis of the 
MDA-MB-435 human breast carcinoma cell line and the KiSS-1 gene suppresses cancer 
metastasis of the C8161 human melanoma cell line.  While both metastasis suppressor genes 
suppress secondary tumor formation without preventing orthotopic tumorigenicity, their 
mechanisms of action are still largely unknown.  Cell culture and SDS-PAGE zymography were 
performed to analyze matrix metalloproteinase (MMP) secretion.  Zymography gels were then 
analyzed by densitometry utilizing the Quantity One software package.  Results of the data 
analysis showed the expression of the BRMS1 and KiSS-1 genes correlate with decreases in 
secretion of specific MMPs from the cells.  In MDA-MB-435, expression of the metastasis 
suppressor gene BRMS1 reduces secretion of MMP-9 and MMP-2.  In C8161, the expression of 
the metastasis suppressor gene KiSS-1 reduces secretion of MMP-9 and MMP-2.  The MMPs are 
believed to play a role in the invasive potential of cells.  By utilizing wound healing assays, the 
invasive potential of the MDA-MB-435 cells were compared to the non-metastatic MDA-MB-
435/BRMS1 cells.  Results showed that expression of BRMS1 in MDA-MB-435 human breast 
carcinoma cells decreased the initial invasiveness of the cells.  These data show that BRMS1 and 
KiSS-1 impact MMP secretion, suggesting this is part of their mechanism of suppression of 
invasive potential and metastasis.  
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LIST OF ABBREVIATIONS 
 
APMA: Aminophenyl mercuric acetate 
BRMS1: BReast cancer Metastasis Suppressor 1 
DME/F-12: Dulbecco’s Modified Eagle’s medium and Ham’s F-12 medium (1:1 mixture) 
ECM: Extracellular matrix 
FBS: Fetal bovine serum 
FISH: Fluorescence in situ hybridization 
EDTA: Ethylenediaminetetraacetic acid 
HBSS: Hanks buffered saline solution 
KP: Kisspeptins 
MMPs: Matrix metalloproteinases 
PAGE: Polyacrylamide gel electrophoesis 
PBS: Phosphate buffered saline 
SDS: Sodium dodecyl sulfate 
TIMPs: Tissue inhibitors of metalloproteinases 
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INTRODUCTION 
 
Cancer Metastasis 
Over 10 million people in the United States have cancer (1).  As a major public health burden, 
cancer accounts for one in four deaths in the United States.  Breast cancer is the most common 
form of cancer in women.  In 2004, almost one-third of the new cases of diagnosed cancer in 
women were breast cancer and it was the second leading cause of cancer death behind lung 
cancer (2).  While incidence of breast cancer has been increasing, advances in prevention, 
detection, and treatment have contributed to declines in mortality during the past few years.  
However, metastatic breast cancer is still incurable (3).  
 
Metastasis is the primary cause of mortality in the more than five hundred thousand patients who 
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Figure 1.  Cancer metastasis involves many highly regulated steps. 
pass away each year due to cancer (1, 2, 4).  Cancer metastasis involves many highly regulated 
steps.  Cells multiply in the absence of control mechanisms to produce a tumor.  Tumor cells 
break off from a primary tumor, invade the surrounding tissue, and migrate through the basal 
membrane and into the circulatory system (intravasation) or lymphatic system.  The cells travel 
and arrest in the blood or lymph vessel before migrating out of the circulatory system 
(extravasation) or lymphatic system.  For some metastatic cells, extravasation is not required as 
tumor cells arrested in the blood vessel can proliferate (5).  Secondary tumor cells must be able 
to grow and thrive in this new secondary environment and secrete signal molecules to induce 
formation of blood vessels (angiogenesis) to provide nutrients to the newly growing tumor (6).  
The many steps of metastasis make it a highly inefficient process. 
 
Cell Lines 
Two of the cell lines chosen for these studies were established in the 1970s.  MDA-MB-231 and 
MDA-MB-435 are breast adenocarcinoma cells that were obtained from Caucasian females in 
1973 and 1976, respectively.  Both cell lines were obtained from a metastatic tumor and 
appeared to be epithelial in origin.  These cells form gradually growing tumors that result in 
metastases when they are injected into the mammary fat pads of immunocompromised mice.  
The MDA-MB-231 cell line was from a 51 year-old patient, while the MDA-MB-435 cell line 
was from a 31 year-old patient (7).  In recent years, argument about the classification of MDA-
MB-435 as a breast carcinoma cell line has surfaced (8).  However, it has been shown that 
MDA-MB-435 cells express milk proteins and metastasize from mammary fat pad but not 
subcutaneous tissue.  This is consistent with breast carcinoma cell lines (9). 
 
Metastasis Suppressor Genes 
Over the years, metastasis suppressors have been significant in metastasis prevention research.  
Metastasis suppressors, a fairly new class of genes with predominately unknown mechanisms of 
action, prevent secondary tumor formation without affecting primary tumor growth (4, 10).  
Metastasis suppressors are different from oncogenes, which promote cellular transformation, and 
tumor-suppressor genes, which suppress tumor growth (11).  This family of more than 25 known 
genes includes the BReast cancer Metastasis Suppressor 1 (BRMS1) and KiSS-1 (12). 
 
The BRMS1 gene is mapped to chromosome 11q13.  It was identified by comparing occurrence 
of metastases in metastatic MDA-MB-435 and metastasis suppressed chromosome 11-MDA-
MB-435 microcell hybrids using a differential display technique (13).  BRMS1 has been shown 
to associate with the SIN3-histone deacetylase complexes possibly altering the transcription of 
some genes (14).  Additionally, BRMS1 has been shown to regulate phosphoinositide signaling 
(15), expression of epidermal growth factor receptor (9), osteopontin (16), NFкB (17), and 
connexins (18), all of which are known to play a significant role in cancer development.  These 
results implicate mechanisms by which BRMS1 suppresses metastasis. 
 
KiSS-1 is a metastasis suppressor gene known to suppress metastasis of the C8161 human 
melanoma cell line without suppressing orthotopic tumorigenicity.  While the mechanism of 
8 
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Figure 2.  Structural domains of MMPs 
(http://www.emdbiosciences.com/html/cbc/matrix_met
alloproteinase_MMP.htm). 
Figure 3.  A Scanning Electron Microscope image of the 
extracellular matrix (Figure 19-35, Molecular Biology of 
the Cell, 4th Edition). 
metastatic suppression by this gene is partially understood, our knowledge is still incomplete.  
The KiSS-1 gene produces the KISS1 metastasis suppressor protein which is secreted and 
converted to kisspeptins (19).  Four biologically active kisspeptins (KP) have been identified: 
KP-54 (metastin), KP-14, KP-13, and KP-10 (20, 21).  It has been shown that the presence of 
kisspeptins is correlated with the suppression of metastasis (19). 
 
MMPs 
The first matrix metalloproteinase (MMP) 
was characterized by Gross and Lapiere in 
1962.  They found that during 
metamorphosis, tadpole tails secreted an 
enzyme that could degrade fibrous collagen, 
the first collagenase (22).  Since that initial 
study, further research has led to the 
classification of a family of structurally 
related proteinases that includes at least 23 
different MMPs in humans and at least 24 
different MMPs in mice.  
 
Gross and Lapiere stated that “precisely timed and localized removal of structural tissue 
elements in delicate balance with 
synthesis is essential to normal growth 
and development (22).”  Previous 
research has revealed that some 
metastatic cancer patients have shown 
secretion of abnormally high levels of 
MMPs from their cells (23).  
Additionally, in animal models, it has 
been shown that relatively benign cancer 
cells acquire malignant properties when 
MMP expression is increased and that 
Figure 4.  A possible model of the secretion pathway of MMPs to 
the extracellular matrix for activation. 
malignant cells become less aggressive when MMP expression is decreased (24).  MMPs are 
proteolytic molecules that are believed to be secreted by all mammalian cells (25).  MMPs are 
secreted from cells in a latent proform and require proteolytic processing for conversion to an 
enzymatically active form.  They 
contain a zinc ion at their active 
site (24, 26).  MMPs function at 
neutral pH and require calcium 
for stability (27).  MMPs 
function as enzymes which 
dynamically regulate the 
extracellular matrix (ECM) by 
degrading its fibrous components 
(28).  MMPs are important in 
tissue remodeling, angiogenesis, 
ovulation and wound healing, but 
they have also been implicated in 
etastasis, atherosclerosis, and 
eted in varying concentrations, and the 
amount of secretion dictates how heavily the ECM is remodeled.  Specific tissue inhibitors of 
metalloproteinases (TIMPs) have been found to inhibit the actions of MMPs, but also have been 
shown to function in the activation processes of specific MMPs (24, 27).  Several clinical trials 
with first generation MMP inhibitors have shown limited effects on suppressing cancer 
metastasis (24, 30). 
 
Hypotheses 
 
? Metastasis suppressors reduce matrix metalloproteinase secretion in metastaic breast 
carcinoma and metastatic melanoma cells. 
? Metastasis suppressors reduce the initial invasive potential in metastatic breast carcinoma 
cells. 
 
many disease processes such as rheumatoid arthritis, tumor cell m
cardiac disease (24, 25, 26, 28, 29).  MMPs are secr
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MATERIALS AND METHODS 
 
Cell Lines and Culture Conditions 
MDA-MB-435, MDA-MB-231, and C8161 human breast carcinoma and melanoma cells were 
cultured in a 1:1 mixture of Dulbecco’s modified Eagle’s medium and Ham’s F-12 medium 
(DME/F-12) with 5% fetal bovine serum (FBS).  Cells were passaged at 80-90% confluency 
using 2.5% Trypsin in Hanks buffered saline solution (HBSS) without calcium or magnesium 
and with 1% EDTA (Hyclone, Logan, UT).  No antibiotics were added to the medium.  Cells 
were cultured in 25-cm2 Corning tissue culture dishes at 37°C with 5% CO2 in a humidified 
atmosphere.  
 
MDA-MB-435 and MDA-MB-231 cells were transfected with full length BRMS1 cDNA under 
the control of the cytomegalovirus promoter.  Cell lines were confirmed to be free of 
Mycoplasma contamination using PCR (TaKaRa, Japan).  The C8161 cells underwent microcell-
mediated transfer of a 40-megabase region of chromosome 6 (chromosomal bands 6q16.3-q23).  
Donor cells containing the neomycin-resistance gene-tagged chromosomal bands 6q16.3-q23 
were used for preparation of the microcell.  After transfection, the C8161 KiSS-1 cells were 
selected in G418-containing media.  Stable microcell hybrids were tested for the region utilizing 
fluorescence in situ hybridization (FISH), karyotyping, and PCR amplification.  The presence of 
the gene was tested for by subcutaneous injection of the cells into the flanks of immunodeficient 
mice (11, 31). 
 
Cell Starvation and Zymography Sample Collection 
Confluent cells in 25-cm2 Corning tissue culture dishes were washed with serum free DME/F-12 
and incubated with serum free DME/F-12 for 6 hours.  Serum free DME/F-12 was removed and 
saved to analyze secreted MMPs.  New serum free medium was added and cells were scraped 
from bottom of dish utilizing a rubber cell scrapper.  The lysate was vortexed on high to further 
lyse the cells and determine retained MMPs within the cells.  Microcon Centrifugal Filter 
Devices, YM-10 (Millipore Corporation, Bedford, MA) were used to concentrate collected 
samples.  Sodium dodecyl sulfate (SDS) sample buffer was added to samples at a 1:1 
concentration. 
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SDS-PAGE Zymography 
SDS-PAGE zymography was used to visualize and detect specific MMPs.  Zymogram gels were 
prepared with 10% separating gel [stock solution: 30% acrylamide mix, 1.5 M Tris (pH 8.8), 
10% SDS, 10% ammonium persulfate, Gelatin Type A, TEMED] and 5% stacking gel [stock 
solution: 30% acrylamide mix, 1.0 M Tris (pH 6.8), 10% SDS, 10% ammonium persulfate, 
TEMED].  Samples were activated by incubating MMP samples in 10 mM aminophenyl 
mercuric acetate (APMA) at a 10:1 concentration for 2 hours at 37°C.  Samples were loaded and 
run at 120 mV in 1x SDS Running Buffer. Gels were removed from glass plates, rinsed with 
water, then soaked in 2.5% Triton-100x for 45 minutes on a shaker.  Gels were then transferred 
to a digesting solution [50 mM Tris-HCL (pH 8), 10 mM CaCl2, 1µM ZnCl2] and incubated at 
37°C for 24 hours with light shaking.  Following incubation, gels were stained with Coomassie 
Brilliant Blue overnight and destained with destaining solution [40% methanol, 10% acetic acid] 
until bands of lysis were clear. 
 
Statistical Analysis 
SDS-PAGE zymography gels were analyzed utilizing densitometry (Quantity One software).  
MMP secretion densities could be quantitatively measured by recording the transparency of each 
band with beams of light.  The data were analyzed in Microsoft Excel using box plots and a 
pooled variance t-test.  T-tests evaluated the statistical significance between the metastasis 
suppressor and control cells and were performed assuming equal variances. 
 
Wound Healing Assay 
MDA-MB-435 human breast carcinoma cells were cultured in DME/F-12 with 5% FBS.  Cells 
were passaged at 80-90% confluency using 2 mM EDTA in 0.1 µM phosphate buffered saline 
solution (PBS) without calcium or magnesium.  Cells were cultured in flat bottom 6-well tissue 
culture plates at 37°C with 5% CO2 in a humidified atmosphere.  
 
MDA-MB-435 and MDA-MB-231 cells were transfected with full length BRMS1 cDNA as 
stated above and cultured parallel to the MDA-MB-435 cells and MDA-MB-231 cells.  The cells 
were cultured to 90-100% confluency in 6-well plates and a linear streak was created by scraping 
across the cell culture with a 0.1-10 µL sterile pipette tip.  The wells were washed with DME/F-
12 
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Figure 5.  In-gel zymography showing MMP activities in human 
carcinoma cell lines MDA-MB-231, MDA-MB-231/BRMS1, MDA-MB-
435, & MDA-MB-435/BRMS1. 
12 with 5% FBS and new 5% FBS supplemented DME/F-12 was replaced on the cells.  The 
wound was imaged with a microscope at five locations along the wound at 0 hours and 18 hours.  
In between imaging, the cells were incubated at 37°C with 5% CO2 in a humidified atmosphere.  
Following imaging, the width of the wounds were measured and statistically analyzed with 
replicates. 
 
RESULTS AND DISCUSSION 
Data from in-gel zymography have shown that in MDA-MB-435, the expression of the 
metastasis suppressor gene BRMS1 reduces secretion of MMP-9 and MMP-2 (Fig. 5 and Fig. 6).  
However, in MDA-MB-231, the expression of the metastasis suppressor gene BRMS1 does not 
show the same reduction 
in secretion of MMPs 
(Fig. 5 and Fig. 6).  
Additionally, in C8161, 
the expression of 
tastasis suppressor 
KiSS-1 reduces 
secretion of MMP-9 and 
MMP-2 (Fig. 7 and Fig. 
8).  These results suggest 
that BRMS1 may reduce 
the invasive potential of 
MDA-MB-435 cells by reducing the expression of MMP-9 and MMP-2, but may function 
differently in MDA-MB-231 cells.  KiSS-1 may reduce the invasive potential of C8161 by 
reducing the expression of MMP-9 and MMP-2.  In some metastatic tumor cells, MMP-9 and 
MMP-2 have been found to be secreted at abnormally high levels.  In MDA-MB-435 and C8161 
cells, reducing MMP secretion may contribute to metastasis suppression. 
 
me
gene 
Active MMP-9
231 231/BRMS1 435 435/BRMS1
Active MMP-2
231 231/BRMS1 435 435/BRMS1
Active MP-9
Active P-2
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Figure 7.  In-gel zymography showing MMP activities in human 
melanoma cell lines C8161 & C8161-KISS1. 
Figure 6.  Graphs showing the densitometry analysis of activated MMP-9 and MMP-2 from the in-gel 
zymography of human carcinoma cell lines MDA-MB-231, MDA-MB-231/BRMS1 MDA-MB-435, & MDA-
MB-435/BRMS1.  Volume refers to the volume integration method that was used to compare the relative 
intensity of different bands on the scanned gel.  Each pixel of the scanned gel was assigned a numerical value 
corresponding to the optical density of the gel at that point.  The numerical value of each pixel within a rectangle 
was added together to determine the volume (the amount of sample contained within the rectangle). 
Active MMP-2
C8161 KiSS1
Active MMP-9
C8161 KiSS1
Active MP-9 Active P-2
 
 
 
 
 
 
 
 
 
 
 
 
 
Active MMP-9
7000
8000
9000
10000
11000
12000
V
ol
um
e
6000
MDA-MB-435 MDA-MB-435/BRMS1
Active MMP-2
6000
7000
8000
9000
10000
11000
12000
MDA-MB-231 MDA-MB-231/BRMS1
V
ol
um
e
Active MMP-2
6000
7000
8000
9000
10000
11000
12000
MDA-MB-435 MDA-M B-435/BRMS1
V
ol
um
e
Active MMP-9
7000
8000
9000
10000
11000
12000
V
ol
um
e
6000
M DA-M B-231 M DA-M B-231/BRM S1
Active MMP-9
6000
7000
8000
9000
10000
11000
12000
C8161 C8161/KiSS-1
V
ol
um
e
Active MMP-2
6000
7000
8000
9000
10000
11000
12000
C8161 C8161/KiSS-1
V
ol
um
e
15 
Figure 8. Graphs showing the densitometry analysis of activated MMP-9 and MMP-2 from the in-gel 
zymography of human melanoma cell lines C8161 & C8161-KISS1.  Volume refers to the volume integration 
method that was used to compare the relative intensity of different bands on the scanned gel.  Each pixel of the 
scanned gel was assigned a numerical value corresponding to the optical density of the gel at that point.  The 
numerical value of each pixel within a rectangle was added together to determine the volume (the amount of 
sample contained within the rectangle). 
Figure 9. Wound-healing assay of MDA-MB-435 and MDA-MB-
435/BRMS1 at 0 hr (top row) and at 18 hrs after wounding with pipet tip 
(bottom row). 
 
 
DA-MB-435 and the MDA-MB-
ed.  The wound was created with a pipette 
tip and was measured at 
0 hours and 18 hours.  
The relative 
proliferation was 
determined by 
subtracting the final 
average wound width 
from the initial average 
wound width.  This 
relative proliferation 
was averaged with 
several replicates and 
was standardized as a 
percent of the maximum 
 
To determine potential differences in motility between the M
435/BRMS1 cells, a wound-healing assay was perform
MDA-MB-435 MDA-MB-435/BRMS1
0 hrs
18 hrs
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mum) was 
measured between the MDA-MB-435 and MDA-MB-435/BRMS1 from the wound healing 
assay. *Two-sample t-test assuming unequal variance showed a statistically significant 
difference (P = 5.811E-5). 
proliferation by the cells.  The MDA-MB-435 cells migrated more rapidly than the MDA-MB-
435/BRMS1 cells (Fig. 9 and Fig. 10).  After 18 hours of incubation, the wound created by 
scraping with a pipette tip was almost completely healed in the MDA-MB-435 cells.  In contrast, 
the migration activity for the MDA-MB-435/BRMS1 cells was considerably slower. 
 
 
 
Th
e wound healing assay was repeated with the MDA-MB-231 cells and the MDA-MB-
231/BRMS1 cells.  The MDA-MB-231 cells showed a similar migration pattern relative to the 
MDA-MB-231/BRMS1 cells (Fig 11 and Fig. 12).  After 18 hours of incubation, the wound 
created by scraping with a pipette tip was almost completely healed in the MDA-MB-231 cells 
as well as in the MDA-MB-231/BRMS1.  This suggests that the MDA-MB-231/BRMS1 may 
inhibit invasiveness of the MDA-MB-231 cells by a different means than the MDA-MB-435 
cells. 
Figure 10. Average relative proliferation (mobility as a percent of the maxi
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Figure 11. Wound-healing assay of MDA-MB-231 and MDA-MB-
231/BRMS1 at 0 hr (top row) and at 18 hrs after wounding with pipet tip 
(bottom row).
Figure 12. Average relative proliferation (mobility as a percent of the 
maximum) was measured between the MDA-MB-231 and MDA-MB-
231/BRMS1 from the wound healing assay. Two sample t-test assuming 
unequal variance did not show a statistical difference (P = 3.975E-2). 
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FUTURE WORK 
 
This work has shown that the expression of the metastasis suppressor gene BRMS1 in the MDA-
MB-435 cells reduces secretion of MMP-9 and MMP-2.  However, the expression of the 
metastasis suppressor gene BRMS1 in the MDA-MB-231 cells does not reduce secretion of these 
MMPs  The expression of metastasis suppressor gene KiSS-1 in the C8161 cells reduces 
secretion of MMP-9 and MMP-2.  Also, the MDA-MB-435 cells migrate faster than MDA-MB-
435/BRMS1 cells, although the MDA-MB-231 cells migrate at a comparable rate as the MDA-
MB-231/BRMS1 cells.  These results imply that the reduction in specific MMP secretion in the 
MDA-MB-435 cells may reduce the invasive potential of the metastatic cancer cells.  Additional 
work should be done to determine the mechanisms that regulate the differential MMP secretion 
to further the understanding of these metastasis suppressors.  This understanding may allow the 
development of new therapeutics for the treatment and prevention of metastatic cancers. 
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Figure 1. Differences in latent MMP3 
secretion from control (MDA-MB-435) and 
BRMS suppressor (MDA-MB-435/BRMS1) 
cells. 
Figure 2. Differences in active MMP3 
secretion from control (MDA-MB-435) and 
BRMS suppressor (MDA-MB-
435/BRMS1) cells. 
Figure 3. Differences in latent MMP2 
secretion from control (C8161) and KISS1 
suppressor (C8161 KiSS-1) cells. 
Figure 4. Differences in active MMP2 
secretion from control (C8161) and KISS1 
suppressor (C8161 KiSS-1) cells. 
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